Allarity Therapeutics, Inc. Common Stock
Symbol: ALLR (NASDAQ)
1.66
▼ (-0.30%) -0.005
Company Description:
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
Key Stats
- Today's Open: $1.65
- Today's High: $1.69
- Today's Low: $1.58
- Today's Volume: 667.72K
- Yesterday Close: $1.66
- Yesterday High: $1.88
- Yesterday Low: $1.64
- Yesterday Volume: 844.23K
- Last Min Volume: 55
- Last Min High: $1.655
- Last Min Low: $1.655
- Last Min VWAP: $1.655
Company Profile
- Name: Allarity Therapeutics, Inc. Common Stock
- Website: https://www.allarity.com
- Listed Date: 2021-12-21
- Location: BOSTON, MA
- Market Status: Active
- CIK Number: 0001860657
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $24.27M
- Round Lot: 100
- Outstanding Shares: 14.62M
- Asset Type: CS
RECENT FILINGS FOR ALLR
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-27 | 8-K | View |
| 2025-08-15 | 10-Q | View |
| 2025-08-14 | NT 10-Q | View |
| 2025-07-16 | 8-K | View |
| 2025-07-14 | 3 | View |
| 2025-07-07 | 8-K | View |
| 2025-07-01 | 8-K | View |
| 2025-06-30 | 8-K | View |
| 2025-06-24 | RW | View |
| 2025-06-17 | 8-K | View |
| 2025-06-11 | 8-K | View |
| 2025-06-05 | 8-K | View |
| 2025-06-03 | 8-K | View |
| 2025-05-13 | 8-K | View |
| 2025-05-09 | 10-Q | View |
| 2025-05-09 | 8-K | View |
| 2025-05-01 | ARS | View |
| 2025-04-30 | DEFA14A | View |
| 2025-04-30 | DEF 14A | View |
| 2025-04-28 | 8-K | View |
Latest News on ALLR